Shukra Pharmaceuticals (BOM:524632) E10: ₹0.42 (As of Mar. 2026)


BOM:524632 Shukra Pharmaceuticals Ltd BOM:524632
65 GF Score
Price ₹33.05
GF Value ₹8.69
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Shukra Pharmaceuticals E10?

Shukra Pharmaceuticals BOM:524632 +4.32% 65 E10 is ₹0.42 as of Mar. 2026. GuruFocus rates BOM:524632 with a GF Score™ of 65/100 and a GF Value™ of ₹8.69 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Shukra Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was ₹-0.040. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹0.42 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Shukra Pharmaceuticals's average E10 Growth Rate was 7.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-07), Shukra Pharmaceuticals's current stock price is ₹33.05. Shukra Pharmaceuticals's E10 for the quarter that ended in Mar. 2026 was ₹0.42. Shukra Pharmaceuticals's Shiller PE Ratio of today is 78.69.

During the past 13 years, the highest Shiller PE Ratio of Shukra Pharmaceuticals was 151.44. The lowest was 11.22. And the median was 38.14.


Shukra Pharmaceuticals  (BOM:524632) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Shukra Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=33.05/0.42
=78.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Shukra Pharmaceuticals was 151.44. The lowest was 11.22. And the median was 38.14.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Shukra Pharmaceuticals E10 Related Terms


Shukra Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Shukra Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shukra Pharmaceuticals E10 Chart

Shukra Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 0.00 0.26 0.39 0.42

Shukra Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.39 0.39 0.44 0.42

BOM:524632 vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shukra Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shukra Pharmaceuticals Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shukra Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Shukra Pharmaceuticals's Shiller PE Ratio falls into.


BOM:524632
65GF Score
Shukra Pharmaceuticals Ltd BOM:524632
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shukra Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Shukra Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.04/164.2724*164.2724
=-0.040

Current CPI (Mar. 2026) = 164.2724.

Shukra Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201606 0.005 105.961 0.008
201609 -0.012 105.961 -0.019
201612 0.000 105.196 0.000
201703 0.001 105.196 0.002
201706 0.002 107.109 0.003
201709 0.000 109.021 0.000
201712 0.032 109.404 0.048
201803 -0.001 109.786 -0.001
201806 0.001 111.317 0.001
201809 -0.001 115.142 -0.001
201812 0.000 115.142 0.000
201903 0.014 118.202 0.019
201906 0.000 120.880 0.000
201909 0.001 123.175 0.001
201912 0.014 126.235 0.018
202003 -0.013 124.705 -0.017
202006 0.001 127.000 0.001
202009 0.003 130.118 0.004
202012 0.007 130.889 0.009
202103 -0.003 131.771 -0.004
202106 0.001 134.084 0.001
202109 0.001 135.847 0.001
202112 0.002 138.161 0.002
202203 0.021 138.822 0.025
202206 0.052 142.347 0.060
202209 0.012 144.661 0.014
202212 0.004 145.763 0.005
202303 0.552 146.865 0.617
202306 0.059 150.280 0.064
202309 0.147 151.492 0.159
202312 0.861 152.924 0.925
202403 0.091 153.035 0.098
202406 0.110 155.789 0.116
202409 0.250 157.882 0.260
202412 0.720 158.323 0.747
202503 0.120 157.552 0.125
202506 0.020 159.755 0.021
202509 0.050 162.289 0.051
202512 0.470 163.281 0.473
202603 -0.040 164.272 -0.040

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹0.42 mean?
Shukra Pharmaceuticals (BOM:524632) has a E10 of ₹0.42 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Shukra Pharmaceuticals and its competitors.
Is Shukra Pharmaceuticals' E10 too high?
Shukra Pharmaceuticals' current E10 is ₹0.42. Overall, Shukra Pharmaceuticals has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shukra Pharmaceuticals' E10 compare to ZTS and UTHR?
Shukra Pharmaceuticals' E10 of ₹0.42 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Shukra Pharmaceuticals and its competitors. Shukra Pharmaceuticals's current E10 is ₹0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shukra Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Shukra Pharmaceuticals (BOM:524632) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹8.69, compared to a current price of ₹33.05 — trading 280.3% above its estimated fair value. The current E10 is ₹0.42. Shukra Pharmaceuticals' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Shukra Pharmaceuticals (BOM:524632), the current E10 is ₹0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shukra Pharmaceuticals (BOM:524632) Overvalued in 2026?

Based on GuruFocus' analysis, Shukra Pharmaceuticals stock appears to be overvalued. The current stock price of ₹33.05 is trading 280.3% above its estimated GF Value™ of ₹8.69. GuruFocus considers Shukra Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:524632:

  • E10: ₹0.42
  • GF Value™: ₹8.69 vs. price of ₹33.05 (280.3% above fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the BOM:524632 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shukra Pharmaceuticals Business Description

Address Judges Bunglow Road, Bodakdev, 3rd Floor, Dev House, Opposite WIAA Office, Ahmedabad, GJ, IND, 380054
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
65GF Score

Get the complete analysis for BOM:524632

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹33.05
Price
₹8.69
GF Value